Vocabria 30 mg Tablet
PDF Leaflet Revision Date: 4 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults who are virologically suppressed.
Dosage (summary)
30 mg once daily for oral lead-in; 600 mg IM initiation, then 400 mg IM monthly or 600 mg every 2 months.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; potential for fetal exposure.
Key Drug Interactions
- Rifampicin
- Rifapentine
- Phenytoin
- Carbamazepine
Contraindications
- Hypersensitivity to cabotegravir
- Concomitant use with rifampicin
Common side effects
- Injection site reactions
- Headache
- Nausea
- Rash
Counselling Points
- Adhere to injection schedule
- Monitor for hypersensitivity signs
- Avoid breastfeeding if possible
Serious warnings
- Hypersensitivity reactions
- Hepatotoxicity
- Risk of resistance after discontinuation
Important Disclaimer
The Vocabria 30 mg Tablet professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
